Ramoun Jones, MD
Interventional Pain Medicine · Phoenix, AZNPI 1508898602
Payments from drug & device makers
Across 842 payments — averaging $60.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Painteq LLC$14K
- Abbott$7K
- Foundation Fusion Solutions, LLC$6K
- Aurora Spine, Inc.$6K
- Boston Scientific$4K
- Vertos Medical, Inc.$4K
- plus $10K from 29 others
What the payments were for
- Consulting fees$19,17637%
- Travel & lodging$1,6943%
- Food & beverage$27,01053%
- Education$3,3286%
- Entertainment$1010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Painteq LLC | 70 | $13,672 |
| Abbott | 289 | $7,220 |
| Foundation Fusion Solutions, LLC | 14 | $6,447 |
| Aurora Spine, Inc. | 1 | $5,500 |
| Boston Scientific | 217 | $4,474 |
| Vertos Medical, Inc. | 48 | $3,926 |
| Nevro Corp. | 69 | $1,643 |
| Impactortho, Inc. | 2 | $1,612 |
| Spinal Simplicity, LLC | 14 | $1,266 |
| Nalu Medical, Inc. | 17 | $823 |
| Vertiflex, Inc. | 35 | $642 |
| Goode Surgical Inc | 1 | $580 |
| Spinefrontier, Inc. | 3 | $512 |
| Biotronik NRO, Inc. | 10 | $409 |
| Relievant Medsystems, Inc. | 4 | $400 |
| Curonix LLC | 3 | $279 |
| Medtronic | 2 | $272 |
| SPR Therapeutics, Inc | 5 | $271 |
| AbbVie(2 entities) | 13 | $248 |
| Stimwave Technologies Incorporated | 1 | $180 |
| Stratus Medical, LLC | 1 | $180 |
| Globus Medical | 1 | $140 |
| Acacia Pharma Inc | 1 | $121 |
| Saluda Medical Americas, Inc. | 2 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $78 |
| Flowonix Medical Incorporated | 2 | $75 |
| Amgen | 2 | $44 |
| Protega Pharmaceutials Inc | 1 | $44 |
| Hikma Pharmaceuticals USA | 2 | $42 |
| Almatica Pharma LLC | 2 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Sentynl Therapeutics, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PAINTEQ$12,264
- SILO TFX$5,500
- mild Device Kit$3,031
- Intracept$1,460
- Proclaim IPG$1,059
- PROCLAIM$977
- HA MINUTEMAN G3-R$865
- LIBERTY SI$649
- InSpan$512
- SIJFuse$512
- NanoFuse$512
- Nalu Neurostimulation System$492
- Omnia$468
- Proclaim Family of SCS IPGs$396
- GENERAL PAIN MANAGEMENT$308
- FacetFuse$184
- Octrode SCS Leads$183
- Nimbus$180
- Prospera$144
- Senza$143
How this compares
$51,309 in reported general payments places this provider in the 80th percentile of 64 interventional pain medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 284 | $7,786 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 208 | $7,531 |
| Gabapentin | 281 | $3,463 |
| Pregabalin | 71 | $2,786 |
| Methocarbamol | 87 | $1,728 |
| Tramadol Hcl | 127 | $1,187 |
| Tizanidine Hcl | 101 | $1,168 |
| Oxycodone Hcl | 85 | $1,137 |
| Mupirocin | 111 | $994 |
| Cyclobenzaprine Hcl | 80 | $922 |
| Cephalexin | 90 | $873 |
| Morphine Sulfate | 30 | $859 |
| Duloxetine Hcl | 48 | $621 |
| Hydromorphone Hcl | 29 | $315 |
| Clindamycin Hcl | 18 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAMorphine Sulfate | $42 | $85930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 interventional pain medicine providers in Arizona.
Other interventional pain medicine in Phoenix
- Matthew DoustPhoenix$12M
- Abram BurgherPhoenix$6.6M
- Lisa StearnsPhoenix$852K
- Steven SiwekPhoenix$161K
- Todd TurleyPhoenix$41K
- Jerome GrovePhoenix$21K
- Thomas MoshiriPhoenix$19K
- Adam SiwekPhoenix$14K
- Jarrett LeathemPhoenix$11K
- Ankit PatelPhoenix$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.